Betta Pharmaceuticals Co. Ltd.
en.bettapharma.com
Latest From Betta Pharmaceuticals Co. Ltd.
Breaking Away From Betta, Jacobio Raises China Oncology Development Bar
Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.
Hepalink-Backed HighTide Bets On NASH For Global Markets
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m
Choose Carefully For China Drug Development Success: White Paper
By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Metabolic Disorders
- Alias(es)
- Zhejiang Beta Pharma Co. Ltd.
- Beta Pharmaceutical Inc.
- Zhejiang Beta Pharma Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
China
-
China
-
Asia
- Parent & Subsidiaries
- Betta Pharmaceuticals Co. Ltd.
- Senior Management
- Lieming Ding, MD, CEO
- Contact Info
-
Betta Pharmaceuticals Co. Ltd.
Phone: 571 8613 0357
355 Xingzhong Rd., Yuhang Economic Zone
Hangzhou,
China
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice